Back Order

If a product is labelled ‘Back Order’ then it may take longer for you to receive it. Please add it to your basket and it will be dispatched when received from the supplier. Lead times vary, please contact us on 0345 222 3550 for the latest information.

Clozapine Test - 1

Stock Code: AHP9297

This article has been produced by the suppliers of this product.

The Clozapine Test

Who is this test for?

Any patient who meets criteria for refractory schizophrenia:

  • Inadequate response to treatment despite the sequential use of adequate doses of at least 2 different antipsychotic drugs: at least 1 of the drugs should be a non-clozapine second-generation antipsychotic.

In addition, patients already receiving clozapine:

  • Patients with only a partial treatment response.
  • Patients with possible benign ethnic neutropenia but their status is uncertain.

Although the benefits of clozapine are widely recognised, every individual decision to prescribe clozapine involves a number of questions:

  • How likely is my patient to respond?
  • The average risk of agranulocytosis is about 1 in 250. Some patients have higher risk than others. How do I know the level of my patient’s risk?
  • Apart from trial and error, how do I know what dose to aim for in my patient?

With The Clozapine Test, before making the decision to prescribe, clinicians can be more certain about:

  • The likelihood that an individual patient will respond to treatment.
  • Whether an individual is at high or low risk for agranulocytosis and whether or not they have Benign Ethnic Neutropenia.
  • The starting dose and the optimal target dose.

How does the test work?

  • Treatment response: three independent genetic variants are analysed and inserted into a mathematical model to predict how likely a person is to respond to clozapine.
  • Agranulocytosis risk: a number of genetic variants that are linked to high risk for neutropenia and agranulocytosis are examined. We test for a single genetic variant to determine benign ethnic neutropenia status.
  • Target dose: the function of four metabolising enzymes is evaluated to predict a target dose for clozapine.

The Results


We will give an estimate of the likelihood of response to clozapine as a percentage, with an indication of the range of values in which the true figure must lie. Agranulocytosis We will determine the risk of agranulocytosis within the range of 0.3% to 20%. Benign Ethnic Neutropenia We will give BEN status based on the genetic profile (as opposed to the standard method of estimating status using a blood count history).


We will detail the starting dose of clozapine and the dose likely to give therapeutic plasma concentrations.

We have placed cookies on your device to help make this website better.

Your Basket